Daniel Azuara
Overview
Explore the profile of Daniel Azuara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nadal E, Heeke S, Benzaquen J, Vilarino N, Navarro A, Azuara D, et al.
JCO Precis Oncol
. 2022 Jan;
4:1239-1245.
PMID: 35050781
No abstract available.
2.
Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients
Vargas-Parra G, Del Valle J, Rofes P, Gausachs M, Stradella A, Moreno-Cabrera J, et al.
Hum Mutat
. 2020 Sep;
41(12):2128-2142.
PMID: 32906215
CHEK2 variants are associated with intermediate breast cancer risk, among other cancers. We aimed to comprehensively describe CHEK2 variants in a Spanish hereditary cancer (HC) cohort and adjust the American...
3.
Azuara D, Ausso S, Rodriguez-Moranta F, Guardiola J, Sanjuan X, Lobaton T, et al.
Inflamm Bowel Dis
. 2018 Aug;
24(12):2555-2564.
PMID: 30099509
Background: The risk of developing colorectal cancer (CRC) is increased in patients with inflammatory bowel disease (IBD) of the colon. The aim of the study was to evaluate the effectiveness...
4.
Gausachs M, Borras E, Chang K, Gonzalez S, Azuara D, Delgado Amador A, et al.
Clin Cancer Res
. 2017 Jun;
23(19):5936-5947.
PMID: 28645942
The majority of genomic alterations causing intratumoral heterogeneity (ITH) in colorectal cancer are thought to arise during early stages of carcinogenesis as a burst but only after truncal mutations in...
5.
Santos C, Azuara D, Garcia-Carbonero R, Garcia Alfonso P, Carrato A, Elez M, et al.
Mol Cancer Ther
. 2017 Jun;
16(9):1999-2007.
PMID: 28626084
In metastatic colorectal cancer (mCRC), recent studies have shown the importance to accurately quantify low-abundance mutations of the pathway because anti-EGFR therapy may depend on certain mutation thresholds. We aimed...
6.
Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, et al.
Mol Cancer Ther
. 2016 Apr;
15(5):1106-12.
PMID: 27037411
The clinical significance of low-frequent RAS pathway-mutated alleles and the optimal sensitivity cutoff value in the prediction of response to anti-EGFR therapy in metastatic colorectal cancer (mCRC) patients remains controversial....
7.
Buj R, Mallona I, Diez-Villanueva A, Barrera V, Mauricio D, Puig-Domingo M, et al.
Oncotarget
. 2016 Feb;
7(9):10536-46.
PMID: 26859682
Hypomethylation of DNA is a hallmark of cancer and its analysis as tumor biomarker has been proposed, but its determination in clinical settings is hampered by lack of standardized methodologies....
8.
Lobaton T, Azuara D, Rodriguez-Moranta F, Loayza C, Sanjuan X, de Oca J, et al.
World J Gastroenterol
. 2014 Aug;
20(30):10591-8.
PMID: 25132780
Aim: To investigate the relationship between the methylation status in the SLIT2 and TGFB2 promoters and colonic inflammation in inflammatory bowel disease patients. Methods: We evaluated the methylation status of...
9.
Javier Carmona F, Azuara D, Berenguer-Llergo A, Fernandez A, Biondo S, de Oca J, et al.
Cancer Prev Res (Phila)
. 2013 May;
6(7):656-65.
PMID: 23694962
DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer (CRC) and precursor lesions have been extensively studied. Different panels have been reported attempting to improve current protocols in clinical practice,...
10.
Alva N, Azuara D, Palomeque J, Carbonell T
Exp Physiol
. 2013 Jan;
98(6):1115-24.
PMID: 23355193
There is growing interest in using hypothermia to prevent hypoxic damage in clinical and experimental models, although the mechanisms regulated by hypothermia are still unclear. As reactive oxygen and nitrogen...